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Although life expectancy is a concept that everyone under- 
stands. and attempts to prolong life are widely appreciated, 
the traditional physician-patient relation usually is based on 
short-term goals. such as an improvement in quality of life, 
rather than on the more nebulous attempt to delay death. 
Nonetheless. early death occurs with such alarming fre- 
quency in patients with chronic heart failure that a reduction 
in its incidence has emerged as an important goal in the 
management of these patients. Because death is such a 
noncontroversial endpoint for therapeutic trials, a reduction 
in the number of deaths is now a primary goal of many 
on-going studies. 
Surrogates for a poor prognosis. In evaluating a patient 
with heart failure, the physician usually seeks to classify the 
severity of the disease with the assumption that the greater 
the severity the poorer its prognosis. But on what should the 
definition of severity be based? On the degree of congestion? 
On the degree of exercise intolerance? On the severity of left 
ventricular dysfunction? We now know that these signs and 
symptoms correlate poorly with each other so that patients 
with, for example, a severely dilated and poorly functioning 
left ventricle may exhibit no symptoms and no exercise 
intolerance (1). 
The problem is that heart failure is a multisystem disease 
that involves the heart, the peripheral vasculature. the 
kidney, the sympathetic nervous system, the renin- 
angiotensin system, other circulating hormones, local para- 
crine and autocrine systems and metabolic derangements in 
skeletal muscle. No single criterion may therefore be ade- 
quate to characterize either the severity of the symptoms or 
the likelihood of early death (2). If one chooses to use 
multiple variables. the list of potential candidates is growing 
all the time. The search for surrogates of mortality certainly 
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has merit, however. if not for help in clinical care, then 
certainly in an effort to select patients with a more precisely 
defined risk of death for a clinical trial designed to test a 
therapy to reduce mortality. 
Mechanism of death. To influence mortality in this syn- 
drome, it is important to understand the mechanism of 
death. Most heart disease mortality can be classified into 
that due to mechanical dysfunction of the heart (pump 
failure) and that due to a lethal arrhythmia. Although pa- 
tients with heart failure usually have left ventricular dysfunc- 
tion, recent trials (3) have suggested that as many as 50% of 
the deaths may be related to an arrhythmic episode rather 
than to an aggravation of the underlying mechanical deficit. 
An attempt to sort out the mechanism of death in heart 
failure is of utmost importance if one is to know whether an 
intervention to prevent ventricular fibrillation or an interven- 
tion to improve pump function is the more rational approach 
in a given patient. This distinction depends on the precision 
with which the mechanism of death can be defined. Unfor- 
tunately, in dealing with symptomatic patients whose life- 
style has been altered by disease, a clear distinction between 
pump failure and a lethal arrhythmia is not always possible. 
Even the documentation of ventricular fibrillation in a bed- 
ridden patient with advanced pump failure does not suggest 
that prevention of that ventricular arrhythmia would have 
strikingly prolonged life. Furthermore, instantaneous unex- 
pected death of the type assumed to be caused by an 
arrhythmia has now been documented on several occasions 
to be due to electromechanical dissociation. Thus, the key 
question-how best to prevent death-may be more difficult 
to answer than might have been suspected. 
The present study. In this issue of the Journal, Gradman 
and associates (4) report an analysis of the previously 
published digoxin-captopril trial aimed at delineating those 
baseline factors that were predictive of overall mortality and 
“sudden death” in patients with heart failure not classified 
as severe. The data base was only modest in size, resulting 
in only 47 deaths for analysis, and the three treatment arms 
in the study (placebo, digoxin, captopril) had to be merged 
despite the possibility that these interventions could have 
altered the pattern of mortality. Furthermore, the authors 
did not utilize life table analysis, which would have cor- 
rected for varying follow-up intervals, but apparently simply 
analyzed dead versus living patients regardless of the time of 
death or the follow-up interval for the survivors. Despite 
these weaknesses in power and analysis, however, the data 
are useful in contributing to a growing insight into the factors 
influencing prognosis in heart failure. 
Left ventricular function. As in most previous trials that 
have included enough patients with a sufficiently wide range 
of left ventricular ejection fraction (51, the ejection fraction 
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was statistically a highly significant predictor of mortality. of the heart failure syndrome has been further muddled by 
Ejection fraction itself is a rather crude measurement, and growing concern that a favorable effect of therapy on one 
even in the best of circumstances it is a less than ideal measurement of the severity of the disease may not be 
measure of the functional capacity of the left ventricle. reflected in a favorable effect on another. For example, there 
Therefore, these repeated confirmations of ejection fraction has long been concern that some drugs may improve left 
as a critical determinant of survival suggest that a more ventricular function but have an adverse effect on survival 
precise technique for evaluating ventricular function, if it (7). Furthermore. the recent early termination of two treat- 
were available, might be an even more sensitive marker for ment arms of The Cardiac Arrhythmia Suppression Trial was 
prognosis. The critical prognostic importance of left ventric- precipitated by overwhelming evidence that type Ic drugs 
ular dysfunction should not necessarily be taken as evidence that suppress ventricular premature beats cause an increase 
that the severity of the underlying etiology-specific myocar- in cardiac mortality. These concerns mean that we must now 
dial disease is the major risk factor. Left ventricular dys- address not only the surrogates for mortality from the 
function may progress because of the interplay of biochem- so-called natural history of the disease but also the surro- 
ical, hemodynamic and structural changes that may bear gates for an adverse response to specific therapeutic agents. 
little relation to the initial myocardial insult. Thus a dilated, And these surrogates may not be the same! 
poorly functioning ventricle may largely represent the im- Conclusions. Heart failure is a complicated syndrome. As 
pact of various self-perpetuating processes within the myo- in most complex diseases involving regulatory systems, our 
cardium rather than the end result of an episode of massive analysis is limited to measurements we know how to make. 
myocardial injury. There may yet be exciting observations in the blood, heart. 
Symptomatic indexes of severity of heart failwe huve peripheral vasculature or neuroendocrine system waiting to 
been less lightly linked to prognosis than has left ventricular be discovered. In the meantime, attempts to identify factors 
dysfunction. That the New York Heart Association func- affecting prognosis in heart failure have value not only for 
tional classification can distinguish the likelihood of dying is our efforts to improve clinical decision making, but also for 
hardly surprising and hardly useful, because this classifica- our goal to gain better insight into the crucial mechanisms 
tion is perhaps too crude to be very helpful. Because that influence the syndrome and may yield to therapeutic 
exercise tolerance is a continuous variable that can be efforts. The story is still unfolding. 
quantitated more precisely and can be monitored during 
therapy, its possible value as a prognostic factor is of 
considerable importance. The study of Gradman et al. (4) 
unfortunately did not confirm that quantitative exercise 
tolerance is an independent predictor of survival. However, 
in a larger data base of men in whom gas exchange was 
monitored during exercise, the Veterans Administration 
Cooperative Study. (V-HeFT) demonstrated that peak oxy- 
gen consumption (VO,) is an independent predictor of prog- 
nosis in heart failure (6). 
The attempt of Gradman et al. (4) to analyze separately 
the group with “sudden death” raises concerns already 
addressed about the definition of this event and the unjusti- 
fied assumption that it is due to an arrhythmia. Nonetheless, 
the data do tend to support the notion that ventricular 
tachycardia in heart failure is a poor prognostic marker and 
may increase the risk for an arrhythmic death. 
One of the risks of identifying a surrogate for mortality is 
that clinical investigators may be attracted to using the 
surrogate as a substitute for mortality data. Demonstration 
of an association between a variable and a high risk of death 
does not imply that a favorable alteration in this surrogate is 
necessarily a good prognostic sign. Indeed, the complexity 
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